Multiple Sclerosis

The Multiple Sclerosis pipeline: 44 tracked drugs, 24 approved for this indication.

24 approved / phase 410 Phase 31 Phase 2/33 Phase 22 Phase 14 preclinical / unstaged

Compare the share prices of listed companies in Multiple Sclerosis →

Total attributable cost

$65.6B

$65,612/patient

Drug spend

$35.2B

$35,154/patient

How this is calculated ↗

All US adult MS forms and disability strata (rounded prevalence context) · US

The Multiple Sclerosis pipeline

Key trial results for every approved and late-stage drug: Multiple Sclerosis results by drug.

← all assets